Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 9:23 PM
Ignite Modification Date: 2025-12-25 @ 7:09 PM
NCT ID: NCT04504032
Description: Analysis was performed in the Safety Population, comprised of all participants randomly assigned to study intervention, who received the study intervention. Participants were grouped according to the study intervention they actually received.
Frequency Threshold: 1
Time Frame: Adverse events were collected from the time of consent up to 14 days after the last dose of study treatment (Day 35).
Study: NCT04504032
Study Brief: A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19)
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Rivaroxaban Participants self-administered rivaroxaban 10 milligrams (mg) (1 tablet) orally once daily for 21 days. 0 None 2 219 12 219 View
Placebo Participants self-administered rivaroxaban matching placebo orally once daily for 21 days. 0 None 7 230 11 230 View
Serious Events(If Any):

Serious Events

Term Type Organ System Vocab View
Pancreatitis SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDra 23.0 View
COVID-19 pneumonia SYSTEMATIC_ASSESSMENT Infections and infestations MedDra 23.0 View
Acute kidney injury SYSTEMATIC_ASSESSMENT Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDra 23.0 View
Deep vein thrombosis SYSTEMATIC_ASSESSMENT Vascular disorders MedDra 23.0 View
Malignant hypertension SYSTEMATIC_ASSESSMENT Vascular disorders MedDra 23.0 View
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Dyspnea SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders MedDra 23.0 View
Urinary Tract Infection SYSTEMATIC_ASSESSMENT Infections and infestations MedDra 23.0 View
COVID -19/COVID-19 pneumonia/pneumonia SYSTEMATIC_ASSESSMENT Infections and infestations MedDra 23.0 View
Headache SYSTEMATIC_ASSESSMENT Nervous system disorders MedDra 23.0 View
Hematuria SYSTEMATIC_ASSESSMENT Renal and urinary disorders MedDra 23.0 View